ReleaseWire Connect

An investigation on behalf of investors, who currently hold shares of Costa Inc (NASDAQ:ATX) shares, was announced concerning whether the takeover of Costa Inc by Essilor International for $21.50 per share is unfair to NASDAQ:ATX stockholders.

An investigation on behalf of investors of Sarepta Therapeutics Inc (NASDAQ:SRPT) shares over potential securities laws violations Sarepta Therapeutics Inc. and certain of its directors and officers in connection certain financial statements was announced.

An investigation on behalf of investors in The Men's Wearhouse, Inc. (NYSE:MW) shares was announced concerning whether certain directors of The Men's Wearhouse, Inc. ( breached their fiduciary duties by rejecting the takeover offer for The Men's Wearhouse, Inc. by Jos. A. Bank.

An investigation on behalf of investors of Sanofi (NASDAQ: GCVRZ) shares over potential securities laws violations in connection certain financial statements was announced.

A long-term investor in NYSE:NES shares filed a lawsuit against directors of Nuverra Environmental Solutions Inc over alleged breached of fiduciary duties.

An investigation on behalf of investors of KMG Chemicals, Inc. (NYSE:KMG) shares over potential securities laws violations by KMG Chemicals, Inc. and certain of its directors and officers in connection certain financial statements was announced.

An investigation on behalf of investors, who currently hold shares of Viropharma Inc (NASDAQ:VPHM) shares, was announced concerning whether the takeover of Viropharma Inc by Shire plc for $50.00 per share is unfair to NASDAQ:VPHM stockholders.

An investigation on behalf of investors, who currently hold shares of Anaren, Inc. (NASDAQ:ANEN) shares, was announced concerning whether the takeover of Anaren, Inc. by The Veritas Capital Fund IV, L.P for $28.00 per share is unfair to NASDAQ:ANEN stockholders.

An investigation on behalf of investors of Tremor Video Inc (NYSE:TRMR) shares over potential securities laws violations by Tremor Video Inc and certain of its directors and officers in connection certain financial statements was announced .

An investigation on behalf of investors, who currently hold shares of Santarus, Inc. (NASDAQ:SNTS) shares, was announced concerning whether the takeover of Santarus, Inc. by Salix Pharmaceuticals, Ltd for $32.00 per share is unfair to NASDAQ:SNTS stockholders.